A. Ferrero

发表

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

D. Katsaros, F. Marmé, M. Yunokawa, 2023, The Lancet.

LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma

E. Piovano, M. Barretina Ginesta, F. Marme, 2023, Annals of Oncology.

Gemcitabine plus metronomic 5-ﬂuorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study

C. Intrivici, B. Zaggia, G. Badalamenti, 2022 .

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.

A. Gadducci, A. Lissoni, S. Cosio, 2024, The Lancet. Oncology.